ArticleTrials2023

Correction: A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren's syndrome patients.

Wei Bai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.